ReviewCurrent nutrition reports2026
Resistant Starch as a Functional Nutrient to Control Cardiometabolic Risk Factors in Humans: An Integrative Review.
Review in Current nutrition reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewResistant starch (RS) has been widely investigated as a dietary component with potential metabolic benefits, including improved insulin sensitivity, lipid profile, and inflammatory markers. However, clinical findings remain inconsistent, particularly regarding RS type and dosage. This integrative review aimed to synthesize evidence on the effects of RS consumption in dietary interventions on metabolic and cardiovascular parameters in adults and older adults. RECENT
findingsRS intake, particularly RS2 and RS3, was associated with significant reductions in postprandial glucose, insulin, and HOMA-IR, as well as improvements in total cholesterol, LDL-C, and triglycerides. Additional findings indicated modest decreases in blood pressure and central adiposity, linked to increased short-chain fatty acid production and higher GLP-1 and PYY levels. Despite promising results, methodological heterogeneity and short intervention durations limit the strength of conclusions. RS shows potential as a functional nutrient for cardiometabolic modulation, particularly for glycemic and lipid control. However, longer, standardized clinical trials are required to confirm efficacy and clarify its physiological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.